Investigational drug · Phase 2
SNB-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SNB-101"
First trial start
2026
Mar 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SNB-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SNB-101" as an intervention, largest first.
SN BioScienceIndustry
NCT07391813 · 55 participants (planned) · Start Mar 2026 · Primary completion Dec 2028
Drug: SNB-101 · For: Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)
Sites: Kamenitz, Serbia
SN BioScienceIndustry
NCT04640480 · 21 participants · Start Oct 21, 2020 · Primary completion Jan 5, 2026
Drug: SNB-101 · For: Colorectal Cancer; Breast Cancer; Pancreas Cancer and 4 more
Sites: Seongnam-si, South Korea; Seoul, South Korea · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101.
Park J, Bae SH, Jeon S, et al. · Front Pharmacol 2025
- Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics.
Zarnoosheh Farahani T, Nejadmoghaddam MR, Sari S, et al. · Heliyon 2024
- Reconstituted basement membrane (matrigel) enhances the growth of human glioma cell lines in nude mice.
Akbasak A, Toevs CC, Laske DW · J Neurooncol 1996
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.